Clinicians separate maintenance indications instead of combining agents by default. Bevacizumab is selected for higher-risk biology, such as residual disease or ascites where angiogenesis dominates, whereas low-risk HRD-deficient patients can rely solely on PARP inhibitors to prevent unnecessary toxicity.
HRD status is a continuous variable with an arbitrary diagnostic cutoff rather than a strict binary result. When a patient achieves a complete pathological response to neoadjuvant platinum, clinicians consider PARP inhibitors even if formal genomic testing returned negative.
Inconclusive HRD assays frequently occur following neoadjuvant chemotherapy due to a lack of residual tumor tissue at interval debulking. Rather than indicating an assay failure, the absence of assessable tissue demonstrates an exceptional pathological response to initial systemic treatment.
Clinicians consider PARP re-challenge primarily when progression occurs after a prolonged period off maintenance rather than during active therapy. Due to regulatory shifts and emerging practice patterns, repeat treatment is reserved for BRCA-mutated patients with preserved platinum sensitivity.
